Recent News: Clinical Trials

Share
Print
and/or
19 News Items found
In the Lab
Illustration of how PU-PET localizes to tumors
Bull’s-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place
Collaborative team advances a new approach for imaging a drug that’s been developed to stop cancer growth.
Feature
Model of TGF-beta molecule
An Old Protein Gets a New Look: Researchers Target TGF-ß to Make Immunotherapy More Effective
Drugs that block the action of TGF-ß may make checkpoint inhibitors more effective.
Roundup
ASH meeting signage
Advances in Myeloma, Lymphoma, and Bone Marrow Transplant Announced at the 2018 ASH Meeting
Learn more about the work of MSK researchers being presented at the 2018 meeting of the American Society of Hematology.
In the Clinic
Medical oncologist Jae Park
Longest-Running CAR T Trial Shows Which Patients Benefit Most, Have Fewest Side Effects
The study represents 20 years of research at MSK.
In the Lab
MSK physician­scientist Luis Diaz
Why Do Immune Checkpoint Inhibitors Work for Only Some People with Cancer?
Learn about why checkpoint inhibitors, a class of immunotherapy drugs, 
is paying off — but only for some patients.
In the Clinic
MSK pediatric oncologist and neuroblastoma expert Kim Kramer
FDA Grants Breakthrough Therapy Designation to Omburtamab for Metastatic Neuroblastoma
A drug created at MSK called burtomab reaches an important milestone toward becoming a treatment for metastatic neuroblastoma.
In the Clinic
MSK medical oncologist Luis Diaz, Jr.
The Science Behind the FDA’s Approval of an Immunotherapy for Mismatch Repair–Deficient Cancers
A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.
Feature
Barry Taylor
With MSK Leading the Way, Precision Medicine Links Lab Research to Patient Care
Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.
In the News
Vice President Joe Biden led a roundtable “cancer moonshot” discussion at Memorial Sloan Kettering
Between the Moon and New York City: Vice President Biden Leads MSK Cancer Moonshot Roundtable
Find out what Vice President Joe Biden had to say when he visited MSK for a roundtable “cancer moonshot” discussion.
Decoder
Exceptional responders of new drugs in clinical trials.
What Are Exceptional Responders?
When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.